These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37610113)

  • 1. The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
    Wright AC; Lin GA; Whittington MD; Agboola F; Herron-Smith S; Rind D; Pearson SD
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1078-1083. PubMed ID: 37610113
    [No Abstract]   [Full Text] [Related]  

  • 2. The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
    Tice JA; Walton SM; Sarker J; Moradi A; Chu JN; Herce-Hagiwara B; Fahim SM; Agboola F; Rind D; Pearson SD
    J Manag Care Spec Pharm; 2023 May; 29(5):576-581. PubMed ID: 37121251
    [No Abstract]   [Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data briefing. NICE (National Institute for Clinical Excellence).
    Appleby J
    Health Serv J; 2000 Jun; 110(5708):32. PubMed ID: 11183800
    [No Abstract]   [Full Text] [Related]  

  • 5. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing health States for use in cost-effectiveness analysis.
    Brazier J
    Pharmacoeconomics; 2008; 26(9):769-79. PubMed ID: 18767897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic health technology assessment: challenges and perspectives].
    Zerda A
    Biomedica; 2014; 34(2):161-3. PubMed ID: 24967920
    [No Abstract]   [Full Text] [Related]  

  • 9. Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot.
    Jaksa A; Bloudek L; Carlson JJ; Shah K; Chen Y; Patrick AR; McKenna A; Campbell JD
    Int J Technol Assess Health Care; 2022 Mar; 38(1):e32. PubMed ID: 35357284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical technology assessment, cost-effective adoption, and quality management by hospitals in the 1990s.
    Veluchamy S; Saver CL
    QRB Qual Rev Bull; 1990 Jun; 16(6):223-8. PubMed ID: 2120659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 13. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer's Disease Treatment Using Real-World Evidence in Thailand.
    Kongpakwattana K; Chaiyakunapruk N
    Value Health; 2020 Jun; 23(6):710-718. PubMed ID: 32540228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Searching for a threshold - Not so NICE..
    Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
    J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
    Miners AH; Garau M; Fidan D; Fischer AJ
    BMJ; 2005 Jan; 330(7482):65. PubMed ID: 15601681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment for the NHS in England and Wales.
    Woods K
    Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introducing the National Institute for Health and Clinical Excellence.
    Jaques H
    Eur Heart J; 2012 Sep; 33(17):2111-2. PubMed ID: 23106069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.